Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

224.77 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

98 99 Next >

Should You Forget Pfizer and Buy This Pharma Stock Instead? ↗

April 22, 2026

Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?

Via The Motley Fool

Topics Intellectual Property

Growth in Non-Surgical Aesthetic Treatments Reported Across Tampa Bay Locations

April 21, 2026

Via Press Release Distribution Service

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗

April 21, 2026

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Via The Motley Fool

The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond ↗

April 19, 2026

These stocks pay juicy dividends but also offer much more.

Via The Motley Fool

Topics Economy

3 Stocks I Plan to Hold for the Next 20 Years ↗

April 18, 2026

These stocks are keepers.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

The Psychedelic Revolution in Mental Healthcare ↗

April 17, 2026

Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and...

Via The Motley Fool

Why AbbVie Is a No-Brainer Stock to Buy on the Dip ↗

April 16, 2026

The pharma giant is still a rock-solid dividend stock.

Via The Motley Fool

1 Value Stock Worth Your Attention and 2 That Underwhelm

April 16, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the Market ↗

April 15, 2026

These stocks pay between 3.3% and 6.3% and are backed by strong financials.

Via The Motley Fool

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

This Indicator Has Called Every Recession Over the Last 80 Years. Here's What It's Saying Now. ↗

April 14, 2026

The U.S. economy could be starting a vicious cycle if this indicator is right.

Via The Motley Fool

Topics Economy

2 S&P 500 Stocks with Solid Fundamentals and 1 We Brush Off

April 14, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Via StockStory

Topics Stocks

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Topics Earnings Economy Intellectual Property

S&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend. ↗

April 13, 2026

There are still some generous yielders if you know where to look.

Via The Motley Fool

Topics Stocks

3 Market-Beating Stocks with Competitive Advantages

April 10, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Via StockStory

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

Topics Bonds

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation ↗

April 09, 2026

The calendar says it’s spring, but investors can’t be blamed for feeling like it’s Groundhog Day: The economic issues impacting portfolios continue to persist this year. Just after a ceasefire between...

Via MarketBeat

Topics Economy

3 Companies Aggressively Raising Dividends While Others Play Defense ↗

April 09, 2026

A strong dividend stock may not only pay a healthy distribution, but also be able to continue to grow its payouts thanks to steady, strong business.

Via MarketBeat

Topics Artificial Intelligence Economy

This Investor's $5 Million ETF Buy Pushes 2028 Bond Fund to Nearly 4% of AUM ↗

April 09, 2026

The Invesco BulletShares 2028 Corporate Bond ETF holds a diversified portfolio of investment-grade U.S. corporate bonds maturing in 2028.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

This Fund's Ladder Strategy Expanded With a $4 Million Buy in One 2027 Bond ETF ↗

April 09, 2026

This ETF targets investment-grade U.S. corporate bonds maturing in 2027, offering defined duration and a predictable income stream.

Via The Motley Fool

Topics Bonds ETFs

Red Spruce Adds $3.35 Million to a 2029 Bond ETF With 4.5% Yield. Here's What Investors Should Know ↗

April 09, 2026

The Invesco BulletShares 2029 Corporate Bond ETF targets investment-grade U.S. bonds maturing in 2029 with a defined maturity structure.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

1 Healthcare Stock on Our Watchlist and 2 We Avoid

April 09, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Via StockStory

3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗

April 08, 2026

These stocks offer high yields and trade at incredibly low earnings multiples.

Via The Motley Fool

Topics Economy

This Pharma Dividend Has Been Raised Every Single Year for Over a Decade ↗

April 07, 2026

Spun off from a Dividend King in 2013, this pharmaceutical stock is a rising star among dividend growth stocks.

Via The Motley Fool

Topics Intellectual Property

Should You Buy AbbVie Stock Before April 29? ↗

April 07, 2026

The healthcare giant reports earnings in three weeks.

Via The Motley Fool

Topics Intellectual Property

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory ↗

April 02, 2026

Dividend payers might become more popular if the recent volatility continues. These two stocks are great picks to weather the storm.

Via The Motley Fool

Topics Economy Retirement Stocks

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

98 99 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.